Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The immune system has a key role to play in controlling cancer initiation and progression. T cell activation, which is central to anti-tumor immune responses, coincides with changes in cellular metabolism. Naïve T cells predominantly require an ATP generating metabolic profile, whereas proliferating effector T cells require anabolic metabolic profiles that promote rapid growth and proliferation. Furthermore, specific T cell subsets require distinct energetic and biosynthetic pathways to match their functional requirements. The often hostile tumor microenvironment can affect T cell immune responses by altering the resulting cellular metabolism. Tailoring immune responses by manipulating cellular metabolic pathways may provide an exciting new option for cancer immunotherapy. T cell responses might also be skewed via metabolic manipulation to treat the complications of obesity-associated inflammation, which is a rapidly growing global health problem and a major risk factor for many malignancies. In this review, the diverse metabolic requirements of T cells in anti-tumor immunity are discussed, as well as the profound influence of the tumor microenvironment and the possible avenues for manipulation to enhance anti-tumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Therefore, it can be concluded from this evidence that the success of ipilimumab in the treatment of malignant melanoma (101) might be in part due to its negative effects on glucose metabolism.”
BackgroundWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“T cell exhaustion is defined by poor effector function, continued expression of inhibitory receptors, and a gene expression profile distinct from TEFF or TMEM cells (74).”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · cited 1×
“Our group have previously shown that activated IFN-γ producing CD4 and CD8 T cells are significantly enriched in obese VAT, while others have found that frequencies of TREG cells are decreased (9, 123, 124).”
BackgroundDifferentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 1×
“Activated T cells must engage distinct transcriptional programs to both establish their differentiation status and elicit the effector functions required (22).”
BackgroundPhosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Tumor cells and non-malignant stromal cells can elicit immunosuppressive effects through the expression of amino acid catabolic enzymes, such as indoleamine 2,3-dioxygenase (IDO) which catalyzes the degradation of tryptophan (65).”
BackgroundHIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140 · cited 2×
“dependent up-regulation of c-Myc in the first 24 h following T cell activation is crucial in the transition from a naïve T cell to a TEFF cell (21).”
BackgroundMethodMichalek, R. D., Gerriets, V. A., Jacobs, S. R., Macintyre, A. N., MacIver, N. J., Mason, E. F., Sullivan, S. A., Nichols, A. G., & Rathmell, J. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003613 · Cited by 2,091
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020 · cited 1×
“HIF-1α is responsible for the glycolytic response that occurs downstream of mTORc1 activation (46).”
BackgroundRabinowitz, J. D., & White, E. (2010) · Science · doi:10.1126/science.1193497 · Cited by 1,982
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Obesity-induced inflammatory changes in adipose tissue
Wellen, K. E., & Hotamisligil, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320514 · Cited by 1,823
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., & Chi, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110278 · Cited by 1,803 · cited 2×
“A few studies have shown that HIF-1α plays an important role in the differentiation of Th17 cells, which are highly glycolytic and are believed to rely more on glycolysis than other T cell subsets (49).”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595 · cited 3×
“It is therefore likely that the constant state of low level inflammation present in many tumors may be due, at least in part, to HIF-1α directed Th17 cell differentiation and decreased TREG cell differentiation (50).”
InfluentialmTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 2×
“Treatment of mice with rapamycin following viral infection not only enhanced frequencies but also accelerated the transition from TEFF cells to virus specific TMEM cells without inhibiting the ability of the infected animal to clear the antigen (111).”
BackgroundEnhancing CD8 T-cell memory by modulating fatty acid metabolism
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., & Choi, Y. (2009) · Nature · doi:10.1038/nature08097 · Cited by 1,559 · cited 4×
“In comparison, the long lifespan of memory T cells (TMEM) poses a different metabolic demand and to facilitate this need, TMEM cells utilize fatty acid oxidation (FAO) as their main energy source (10).”
BackgroundInfluentialMitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development
van der Windt, G. J. W., Everts, B., Chang, C.-H., Curtis, J. D., Freitas, T. C., Amiel, E., Pearce, E. J., & Pearce, E. L. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.007 · Cited by 1,540 · cited 2×
“This results in TMEM cells having a survival advantage over TEFF cells in the absence of pro-glycolysis signals, when the initial priming antigen has been eliminated and cytokines such as IL-2 dissipate (37).”
BackgroundMcGeachy, M. J., Bak-Jensen, K. S., Chen, Y., Tato, C. M., Blumenschein, W., McClanahan, T., & Cua, D. J. (2007) · Nature Immunology · doi:10.1038/ni1539 · Cited by 1,520 · cited 1×
“Development of pathogenic Th17 cells is dependent on exposure to IL 23, which diminishes the production of the anti-inflammatory cytokine IL-10 (55).”
BackgroundShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
The CD28 Signaling Pathway Regulates Glucose Metabolism
Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475 · cited 1×
“CTLA-4 also inhibits increased glucose metabolism following T cell activation which is highly relevant as increased glucose metabolism is vital to sustain the increased metabolic demands that occur in the transition of a naïve T cell to a TEFF cell (80, 100).”
BackgroundFueling Immunity: Insights into Metabolism and Lymphocyte Function
Pearce, E. L., Poffenberger, M. C., Chang, C.-H., & Jones, R. G. (2013) · Science · doi:10.1126/science.1242454 · Cited by 1,363 · cited 2×
“The ability of a T cell to transition from a naïve, to effector, to a memory phenotype is determined by metabolism and the metabolic program varies to match the T cell subset in order to enable cell survival and function (2).”
BackgroundHIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335 · cited 1×
“HIF-1α is a master transcriptional regulator in the response to low O2 levels and is also involved in neoplastic pathways, including angiogenesis, cell survival, and treatment resistance (43).”
BackgroundRodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276 · cited 1×
“The resulting lower levels of arginine led to inhibition of T cell receptor expression and antigen specific T cell responses (63).”
BackgroundThe key role of anaplerosis and cataplerosis for citric acid cycle function
Owen, O. E., Kalhan, S. C., & Hanson, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r200006200 · Cited by 1,172 · cited 1×
“It replaces the metabolites that are removed from the TCA cycle for the biosynthesis of fatty acids, nucleotides, and proteins allowing the TEFF cells to maintain the integrity of the TCA cycle function (60).”
BackgroundFrumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · cited 1×
“In combination with other chemotherapeutic agents such as cyclophosphamide, it led to the regression of established tumors in a mouse model of HER-2 breast cancer (95).”
BackgroundInhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z., Roychoudhuri, R., Palmer, D. C., Muranski, P., Karoly, E. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69589 · Cited by 952 · cited 1×
“This resulted in the increased activity of signaling pathways and transcription factors that enhance TMEM cell development, such as AMPK which negatively regulated mTOR and Foxo1, and resulted in enhanced anti-tumor activity of CD8 T cells (106).”
BackgroundExhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845 · cited 1×
“The T cell exhaustion at the metastatic tumor sites was induced by continuous antigen exposure coupled with inhibitory signals from tumor cells and non-malignant stromal cells (77).”
BackgroundCarr, E. L., Kelman, A., Wu, G. S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A. M., & Frauwirth, K. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903586 · Cited by 830
Stability of the Regulatory T Cell Lineage in Vivo
Rubtsov, Y. P., Niec, R. E., Josefowicz, S., Li, L., Darce, J., Mathis, D., Benoist, C., & Rudensky, A. Y. (2010) · Science · doi:10.1126/science.1191996 · Cited by 730 · cited 1×
“The utilization of lipid oxidation by TREG cells might play a central role in their survival advantage over TEFF cells and in the maintenance of a stable pool of pro-tumor immune cells (30).”
BackgroundHypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660 · cited 1×
“have demonstrated that genetically activating the HIF-1α pathway in a B16 mouse melanoma tumor cell line can prevent TEFF cell exhaustion by sustaining the effector functions of T cells despite persistent antigen exposure (98).”
BackgroundRao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.10.010 · Cited by 656 · cited 1×
“Other modes of action investigated for rapamycininduced development of TMEM cells include the inhibition of the Th1 promoting transcription factor T-bet and the stabilization of the expression of the related transcription factor eomesodermin (110).”
BackgroundMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
The inflammation highway: metabolism accelerates inflammatory traffic in obesity
Johnson, A. R., Justin Milner, J., & Makowski, L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01151.x · Cited by 603 · cited 1×
“Unavailability of these fuels occurs during malnutrition and can lead to immunosuppression (7), while excess fuel in diet-induced obesity is associated with a constant low level state of inflammation (8).”
BackgroundCD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability
van der Windt, G. J. W., O’Sullivan, D., Everts, B., Huang, S. C.-C., Buck, M. D., Curtis, J. D., Chang, C.-H., Smith, A. M., Ai, T., Faubert, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221740110 · Cited by 523
mTOR , metabolism, and the regulation of T‐cell differentiation and function
Waickman, A. T., & Powell, J. D. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01152.x · Cited by 420 · cited 6×
“Rapamycin, through the inhibition of mTOR (specifically complex 1) reduces glycolysis and increases lipid oxidation and can also enhance the formation of TMEM cells (36) (Figure 2).”
BackgroundInfluentialDynamic programming of CD8+ T lymphocyte responses
van Stipdonk, M. J. B., Hardenberg, G., Bijker, M. S., Lemmens, E. E., Droin, N. M., Green, D. R., & Schoenberger, S. P. (2003) · Nature Immunology · doi:10.1038/ni912 · Cited by 401 · cited 4×
“Biochim Biophys Acta (2011) 1813(4):645–54.”
BackgroundInfluentialCham, C. M., Driessens, G., O'Keefe, J. P., & Gajewski, T. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200838289 · Cited by 388 · cited 1×
“Glucose is essential for TEFF cell survival and proliferation (5), IFN-γ production (58), and cytolytic activity via production of granzyme and perforin (59).”
BackgroundRevving the Engine: Signal Transduction Fuels T Cell Activation
Jones, R. G., & Thompson, C. B. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.008 · Cited by 349
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252 · cited 1×
“Although to date, the anti-cancer effects of rapamycin and its derivatives are more prominent than the immunosuppressant effects, further research is warranted to ensure this is also the case in the long term (116).”
BackgroundMolecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Heterogeneity of human effector CD4+ T cells
Annunziato, F., & Romagnani, S. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2843 · Cited by 194 · cited 6×
“It is an oxygen dependent process and produces 36 molecules of ATP per glucose molecule (1).”
BackgroundInfluential
Cited by
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
“, 2013), and others (Mellor and Munn, 2008; Mockler et al., 2014; Srivastava et al., 2010), have speculated that nutrient competition in the tumor microenvironment in vivo impacts T cell function.”
BackgroundMetabolomics: beyond biomarkers and towards mechanisms
Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.25 · Cited by 2,829
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“Determining how immune cell metabolism interacts with tumor metabolism, and how this is modulated by drugs targeting metabolic enzymes, might aid in the design of more effective immunotherapies (Buck et al., 2017; Mockler et al., 2014).”
BackgroundEndothelial Cell Metabolism in Normal and Diseased Vasculature
Eelen, G., de Zeeuw, P., Simons, M., & Carmeliet, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.302855 · Cited by 627
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Metadata
- Authors
- Mockler, M. B., Conroy, M. J., & Lysaght, J.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-05-16
- Volume
- 4
- Pages
- 107-107
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2130984411
- Cited by
- 88
- References
- 48
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.